鲁抗医药
(600789)
| 流通市值：53.05亿 | | | 总市值：53.05亿 |
| 流通股本：8.96亿 | | | 总股本：8.96亿 |
| 报告期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 6,146,721,439.54 | 4,731,864,846.81 | 3,186,169,198.27 | 1,669,812,908.04 |
| 营业收入 | 6,146,721,439.54 | 4,731,864,846.81 | 3,186,169,198.27 | 1,669,812,908.04 |
| 二、营业总成本 | 5,907,664,138.07 | 4,571,950,527.78 | 3,067,725,236.26 | 1,615,220,490.91 |
| 营业成本 | 4,631,268,196.9 | 3,634,282,603.74 | 2,494,609,672.63 | 1,258,401,528.88 |
| 税金及附加 | 53,760,813.23 | 39,144,422.66 | 24,407,898.76 | 11,965,674.54 |
| 销售费用 | 577,590,187.29 | 453,407,827.68 | 285,402,333.41 | 199,415,378.86 |
| 管理费用 | 232,620,393.37 | 171,053,426.76 | 101,843,443.06 | 48,693,561.78 |
| 研发费用 | 345,785,127.47 | 229,676,790.19 | 146,959,987.51 | 72,066,772.99 |
| 财务费用 | 66,639,419.81 | 44,385,456.75 | 14,501,900.89 | 24,677,573.86 |
| 其中:利息费用 | 79,174,658.78 | 55,150,991.2 | 33,856,609.53 | 19,169,593.22 |
| 其中:利息收入 | 8,941,607.31 | 6,474,067.7 | 4,744,635.48 | 1,762,287.21 |
| 加:公允价值变动收益 | -68,880 | 14,760 | 61,500 | 14,760 |
| 加:投资收益 | -7,134,141.72 | -3,793,508.77 | -1,985,401.49 | -907,456.95 |
| 资产处置收益 | 282,001.76 | 158,893.59 | 93,204.23 | 93,204.23 |
| 资产减值损失(新) | -54,682,341.19 | -12,008,613.91 | -25,518,614.03 | -10,735,683.83 |
| 信用减值损失(新) | 7,802,086.93 | 20,158,820.36 | 11,220,942.24 | 7,596,067.37 |
| 其他收益 | 86,877,425.21 | 56,735,699.95 | 46,800,460.82 | 4,440,028.97 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 272,133,452.46 | 221,180,370.25 | 149,116,053.78 | 55,093,336.92 |
| 加:营业外收入 | 1,205,345.61 | 752,613.19 | 426,133.29 | 137,898.84 |
| 减:营业外支出 | 363,627.82 | 94,509.46 | 92,598.36 | 47,233.15 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 272,975,170.25 | 221,838,473.98 | 149,449,588.71 | 55,184,002.61 |
| 减:所得税费用 | 16,187,881.1 | 21,892,232.06 | 13,723,123.73 | 7,769,222.25 |
| 六、净利润 | 256,787,289.15 | 199,946,241.92 | 135,726,464.98 | 47,414,780.36 |
| 持续经营净利润 | 256,787,289.15 | 199,946,241.92 | 135,726,464.98 | 47,414,780.36 |
| 归属于母公司股东的净利润 | 246,171,797.53 | 192,551,462.59 | 131,378,322.44 | 45,688,589.04 |
| 少数股东损益 | 10,615,491.62 | 7,394,779.33 | 4,348,142.54 | 1,726,191.32 |
| (一)基本每股收益 | 0.28 | 0.22 | 0.15 | 0.05 |
| (二)稀释每股收益 | 0.28 | 0.21 | 0.14 | 0.05 |
| 八、其他综合收益 | -5,149,302.51 | -3,800,819.55 | -3,800,819.55 | - |
| 归属于母公司股东的其他综合收益 | -5,149,302.51 | -3,800,819.55 | -3,800,819.55 | - |
| 九、综合收益总额 | 251,637,986.64 | 196,145,422.37 | 131,925,645.43 | 47,414,780.36 |
| 归属于母公司股东的综合收益总额 | 241,022,495.02 | 188,750,643.04 | 127,577,502.89 | 45,688,589.04 |
| 归属于少数股东的综合收益总额 | 10,615,491.62 | 7,394,779.33 | 4,348,142.54 | 1,726,191.32 |
| 公告日期 | 2024-03-23 | 2023-10-26 | 2023-08-19 | 2023-04-19 |
| 审计意见(境内) | 标准无保留意见 | | | |